Abstract:Glioblastoma is the most frequent primary brain tumor in the adult, accounting for 53.8% of all gliomas (http://www.cbtrus.org), and it is one of the most deadly among all human tumors. Despite aggressive treatment at diagnosis, consisting of resection followed by radiation with concurrent and subsequent adjuvant chemotherapy with temozolomide, the tumor almost invariably recurs or progresses, with a patient median survival of 14.6 mo (1). The hallmark of glioblastoma that distinguishes it from all of the other glial tumors is microvascular proliferation in conjunction with necrosis. Therefore, treatment with antiangiogenic agents holds great promise to block the growth of this most vascularized tumor. The best-known antiangiogenic agents are inhibitors of VEGF-A, an indispensable angiogenic factor during developmental organogenesis and growth of numerous tumors. However, treatment with bevacizumab, a neutralizing antibody to VEGF-A, at relapse only confers transient benefit and a marginal increase in survival, indicating at tumor progression a VEGF-independent angiogenic mechanism of glioblastoma resistance (2). Several mechanisms have been implicated in angiogenesis. One is the sprouting of capillaries from preexisting blood vessels by endothelial proliferation (3). Another is the cooption of preexisting blood vessels by tumor cells, leading to expression of angiopoietin-2 by those vessels’ endothelial cells and tumor cell proliferation, followed later by involution of preexisting vessels in the core of the tumor, massive tumor cell apoptosis, organization of remaining tumor cells into pseudopalisading that resides around areas of necrosis, and tumor rescue at the margins by angiogenesis (4, 5). Expression of HIF-1α and up-regulation of VEGF-A have been identified in hypoxic perinecrotic pseudopalisading tumor cells (4–6). Hypoxia induces elevated levels of VEGF-A (6) and VEGF-A receptors that appear up-regulated in tumor endothelial cells but not in normal brain (7). Another mechanism is the release of angiogenic factors by the tumor that recruit bone marrow-derived …

Constitutive NF-kappaB Activity Regulates the Expression of VEGF and IL-8 and Tumor Angiogenesis of Human Glioblastoma.

Transcription Factor Nfat5 Promotes Glioblastoma Cell-Driven Angiogenesis Via Sbf2-As1/Mir-338-3p-Mediated Egfl7 Expression Change

NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas

Overexpression of the Kininogen-1 Inhibits Proliferation and Induces Apoptosis of Glioma Cells

Rage Expression In Tumor-Associated Macrophages Promotes Angiogenesis In Glioma

Bmi-1 Promotes Glioma Angiogenesis by Activating NF-κB Signaling.

Angiogenin Promotes U87mg Cell Proliferation By Activating Nf-Kappa B Signaling Pathway And Downregulating Its Binding Partner Fhl3

Knockdown of Nrf2 Suppresses Glioblastoma Angiogenesis by Inhibiting Hypoxia-Induced Activation of HIF-1α.

Nuclear Factor-Kappa B1 Inhibits Early Apoptosis of Glioma Cells by Promoting the Expression of Bcl-2.

A Target For Antiangiogenic Therapy: Vascular Endothelium Derived From Glioblastoma

NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma

Molecular Mechanisms Involved in Angiogenesis and Potential Target of Antiangiogenesis in Human Glioblastomas

The significance of nuclear factor-kappa B signaling pathway in glioma: A review

A Low Level of Tumor Necrosis Factor Α in Tumor Microenvironment Maintains the Self-Renewal of Glioma Stem Cells by Vasorin-mediated Glycolysis

Potential regulatory mechanism of TNF-α/TNFR1/ANXA1 in glioma cells and its role in glioma cell proliferation

Retinol binding protein 1‐dependent activation of NF‐ κB signaling enhances the malignancy of non‐glioblastomatous diffuse gliomas

Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival

The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma

Correlation of Nrf2 and HIF-1α in Glioblastoma and Their Relationships to Clinicopathologic Features and Survival

DGKζ Plays Crucial Roles in the Proliferation and Tumorigenicity of Human Glioblastoma

The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin